| 1. |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022 [J]. CA Cancer J Clin, 2022, 72(1): 7-33.
|
| 2. |
Horino T, Tokunaga R, Miyamoto Y, et al. The impact of the advanced lung cancer inflammation index on the outcomes of patients with metastatic colorectal cancer who receive chemotherapy [J]. Int J Clin Oncol, 2023, 28(3): 400-408.
|
| 3. |
Li MX, Zhang MY, Dong HH, et al. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma [J]. Int J Med Sci, 2021, 18(2): 494-504.
|
| 4. |
Chen H, Wu F, Xu H, et al. Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways [J]. Cancer Gene Ther, 2022, 29(7): 1033-1042.
|
| 5. |
Xu Z, Xu D, You Z, et al. CENPF upregulation is associated with immunosuppressive status and poor clinical outcomes in lung adenocarcinoma validated by qRT-PCR [J]. Comb Chem High Throughput Screen, 2024, 27(1): 78-89.
|
| 6. |
Xie L, Shen K, Wei C, et al. Centromere protein F is a potential prognostic biomarker and target for cutaneous melanoma [J/OL]. Biomedicines, 2025, 13(4): 792. doi:10.3390/biomedicines13040792.
|
| 7. |
Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway [J]. N Engl J Med, 2016, 375(18): 1767-1778.
|
| 8. |
Lee D, Cho M, Kim E, et al. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders [J]. Mol Ther, 2024, 32(12): 4235-4255.
|
| 9. |
Lin KX, Istl AC, Quan D, et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies [J]. Cancer Immunol Immunother, 2023, 72(12): 3875-3893.
|
| 10. |
Singh M, Morris VK, Bandey IN, et al. Advancements in combining targeted therapy and immunotherapy for colorectal cancer [J]. Trends Cancer, 2024, 10(7): 598-609.
|
| 11. |
徐小艷, 王建君, 王慧, 等. JMJD3和Ki-67定量檢測與乳腺浸潤性導管癌分子分型及臨床病理學特征的關系 [J]. 中國癌癥雜志, 2020, 30(1): 57-63.
|
| 12. |
徐小艷, 王建君, 閆琛, 等. 三陰性乳腺癌JMJD3和PTEN的表達與臨床病理特征的關系 [J]. 實用醫學雜志, 2020, 36(19): 2678-2683.
|
| 13. |
Lugli A, Kirsch R, Ajioka Y, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 [J]. Mod Pathol, 2017, 30(9): 1299-1311.
|
| 14. |
Holt SV, Vergnolle MA, Hussein D, et al. Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint [J]. J Cell Sci, 2005, 118(Pt 20): 4889-4900.
|
| 15. |
Tan F, Tang Y, He Z. Role of CCNB1, CENPF, and neutrophils in lung cancer diagnosis and prognosis [J/OL]. Medicine (Baltimore), 2023, 102(46): e35802. doi: 10.1097/MD.0000000000035802.
|
| 16. |
Xie Z, Lin H, Wu Y, et al. USP4-mediated CENPF deubiquitylation regulated tumor metastasis in colorectal cancer [J/OL]. Cell Death Dis, 2025, 16(1): 81. doi: 10.1038/s41419-025-07424-3.
|
| 17. |
Kruczkowska W, Marciniak B, Kontek R. Focus on PD-1/PD-L1-targeting antibodies in colorectal cancer: are there options beyond dostarlimab, nivolumab, and pembrolizumab? A comprehensive review [J/OL]. Molecules, 2025, 30(13): 2686. doi: 10.3390/molecules30132686.
|
| 18. |
Rogers AC, Winter DC, Heeney A, et al. Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer [J]. Br J Cancer, 2016, 115(7): 831-840.
|
| 19. |
Qu Q, Wu D, Li Z, et al. Tumor budding and the prognosis of patients with metastatic colorectal cancer: a meta-analysis [J/OL]. Int J Colorectal Dis, 2023, 38(1): 141. doi: 10.1007/s00384-023-04423-8.
|
| 20. |
Li J, Liu L, Zong G, et al. Knockdown of CENPF induces cell cycle arrest and inhibits epithelial mesenchymal transition progression in glioma [J/OL]. Oncol Lett, 2024, 29(1): 61. doi: 10.3892/ol.2024.14807.
|
| 21. |
Shahid M, Lee MY, Piplani H, et al. Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling [J]. Cell Cycle, 2018, 17(24): 2802-2818.
|
| 22. |
Yu X, Xu J. TWIST1 drives cytotoxic CD8+ T-cell exhaustion through transcriptional activation of CD274 (PD-L1) expression in breast cancer cells [J/OL]. Cancers (Basel), 2024, 16(11): 1973. doi: 10.3390/cancers16111973.
|
| 23. |
Tang X, Sui X, Weng L, et al. SNAIL1: linking tumor metastasis to immune evasion [J/OL]. Front Immunol, 2021, 12: 724200. doi: 10.3389/fimmu.2021.724200.
|
| 24. |
Yang L, Xue R, Pan C. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis [J]. Onco Targets Ther, 2019, 12: 3671-3682.Yang L, Xue R, Pan C. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis [J]. Onco Targets Ther, 2019, 12: 3671-3682.
|